Compare AJANTA PHARMA with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA NOVARTIS AJANTA PHARMA/
NOVARTIS
 
P/E (TTM) x 27.7 2,166.7 1.3% View Chart
P/BV x 6.9 28.8 23.8% View Chart
Dividend Yield % 0.5 1.5 33.5%  

Financials

 AJANTA PHARMA   NOVARTIS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
NOVARTIS
Mar-19
AJANTA PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,422980 145.1%   
Low Rs898600 149.6%   
Sales per share (Unadj.) Rs233.5198.7 117.5%  
Earnings per share (Unadj.) Rs44.021.0 209.7%  
Cash flow per share (Unadj.) Rs52.222.3 234.3%  
Dividends per share (Unadj.) Rs9.0010.00 90.0%  
Dividend yield (eoy) %0.81.3 61.3%  
Book value per share (Unadj.) Rs255.1307.5 83.0%  
Shares outstanding (eoy) m88.0224.69 356.5%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.04.0 124.9%   
Avg P/E ratio x26.437.7 70.0%  
P/CF ratio (eoy) x22.235.5 62.6%  
Price / Book Value ratio x4.52.6 176.9%  
Dividend payout %20.547.7 42.9%   
Avg Mkt Cap Rs m102,08119,508 523.3%   
No. of employees `0006.80.6 1,170.4%   
Total wages/salary Rs m4,3071,171 367.8%   
Avg. sales/employee Rs Th3,022.68,445.4 35.8%   
Avg. wages/employee Rs Th633.42,015.7 31.4%   
Avg. net profit/employee Rs Th569.1891.0 63.9%   
INCOME DATA
Net Sales Rs m20,5544,907 418.9%  
Other income Rs m211783 26.9%   
Total revenues Rs m20,7655,689 365.0%   
Gross profit Rs m5,664123 4,612.6%  
Depreciation Rs m72132 2,266.7%   
Interest Rs m1216 73.0%   
Profit before tax Rs m5,143858 599.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,273340 374.4%   
Profit after tax Rs m3,870518 747.5%  
Gross profit margin %27.62.5 1,101.2%  
Effective tax rate %24.839.6 62.4%   
Net profit margin %18.810.6 178.4%  
BALANCE SHEET DATA
Current assets Rs m11,8128,055 146.7%   
Current liabilities Rs m3,7761,850 204.1%   
Net working cap to sales %39.1126.4 30.9%  
Current ratio x3.14.4 71.8%  
Inventory Days Days7745 171.9%  
Debtors Days Days8234 240.6%  
Net fixed assets Rs m14,398150 9,611.7%   
Share capital Rs m175123 142.1%   
"Free" reserves Rs m22,2777,469 298.3%   
Net worth Rs m22,4527,592 295.7%   
Long term debt Rs m70-   
Total assets Rs m26,9629,824 274.4%  
Interest coverage x444.354.9 808.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.5 152.6%   
Return on assets %14.45.4 265.0%  
Return on equity %17.26.8 252.8%  
Return on capital %23.011.5 199.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68258 18,544.6%   
Fx outflow Rs m2,1021,326 158.5%   
Net fx Rs m8,580-1,269 -676.3%   
CASH FLOW
From Operations Rs m3,748-1,943 -192.9%  
From Investments Rs m-2,2282,742 -81.2%  
From Financial Activity Rs m-1,475-298 494.5%  
Net Cashflow Rs m45501 9.0%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 2.0 77.5%  
FIIs % 7.6 1.6 475.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 21.5 79.1%  
Shareholders   20,968 41,647 50.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   FULFORD INDIA  VENUS REMEDIES  CIPLA  WOCKHARDT  SUVEN LIFE SCIENCES  

Compare AJANTA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Plunged 2% Today(Closing)

Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 27, 2021 03:36 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS